NEWS HIGHLIGHTS
Published Studies Related to Transderm Nitro (Nitroglycerin Transdermal)
Intravenous nitroglycerin for external cephalic version: a randomized controlled trial. [2009.09]
OBJECTIVE: To estimate whether treatment with intravenous nitroglycerin for uterine relaxation increases the chance of successful external cephalic version... CONCLUSION: Treatment with intravenous nitroglycerin increased the rate of successful external cephalic version in nulliparous, but not in multiparous, women. Treatment with intravenous nitroglycerin appeared to be safe, but our numbers were too small to rule out rare serious adverse effects. LEVEL OF EVIDENCE: I.
Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. [2009.09]
CONTEXT: Osteoporosis is common among postmenopausal women; animal studies and human pilot studies support the concept of nitric oxide (NO) donors reducing bone mineral density loss. OBJECTIVE: The objective of the study was to evaluate whether NO donor, nitroglycerin, prevents postmenopausal bone loss... CONCLUSIONS: BMD changes did not substantially differ between postmenopausal women who received the dose of nitroglycerin tested, in comparison with a placebo. Once-daily dosing with 22.5 mg of transdermal-administered nitroglycerin was not effective (compliance adjusted dose was only approximately 16 mg/d); a sub-therapeutic dose.
Effects of nitroglycerin on sublingual microcirculatory blood flow in patients with severe sepsis/septic shock after a strict resuscitation protocol: A double-blind randomized placebo controlled trial. [2009.08.27]
OBJECTIVES:: Microcirculatory alterations have been associated with morbidity and mortality in human sepsis. Such alterations occur despite pressure-guided resuscitation. Earlier data suggested that impaired microcirculatory blood flow could be corrected with intravenous nitroglycerin in these patients. We tested this concept after fulfillment of preset systemic hemodynamic resuscitation end points in the early phase of sepsis... CONCLUSIONS:: In the context of a strict resuscitation protocol, based upon fulfillment of systemic hemodynamic end points in patients with early-phase severe sepsis or septic shock, we conclude that intravenous nitroglycerin does not promote sublingual microcirculatory blood flow.
The effect of nitroglycerin as an adjuvant to lidocaine in intravenous regional anesthesia. [2009.06]
PURPOSE: The disadvantages of intravenous regional anesthesia (IVRA) include slow onset, poor muscle relaxation, tourniquet pain, and rapid onset of pain after tourniquet deflation. In this randomized, double-blind study, we evaluated the effect of nitroglycerin (NTG) in quality improvement when added to lidocaine in IVRA... CONCLUSION: The NTG adding to lidocaine in intravenous regional anesthesia shortens onset times of sensory and motor block and decreases the tourniquet and postoperative pain, without any side effect.
Transdermal nitroglycerin as an adjuvant to patient-controlled morphine analgesia after total knee arthroplasty. [2009.03]
BACKGROUND: Nitroglycerin (NTG) has been shown to be a useful adjunct for pain treatment without increasing adverse side effects. The effects of NTG on postoperative morphine consumption after knee replacement were evaluated... CONCLUSIONS: The use of NTG patches conferred no advantage over the use of placebo in patients receiving patient-controlled morphine analgesia after total knee replacement. Two myocardial infarcts occurred in this group. Therefore, the safety of postoperative NTG patch use for pain control must be questioned.
Clinical Trials Related to Transderm Nitro (Nitroglycerin Transdermal)
Scopolamine to Treat Depression
This study will examine the antidepressant effects of scopolamine in patients with major
depressive disorder or bipolar disorder. Scopolamine is commonly used to treat motion
sickness and diarrhea, and is sometimes given before anesthesia or during eye examinations.
In preliminary studies, scopolamine has shown strong antidepressant effects when given as an
intravenous (through a vein) infusion. This study will examine its effectiveness when given
through a skin patch and in pill form.
People between 18 and 50 years of age who have major depressive disorder or bipolar disorder
may be eligible for this study. Candidates are screened with a physical exam,
electrocardiogram (EKG), eye exam, blood and urine tests, psychiatric and clinical interviews
and neuropsychological testing.
Participants wear skin patches behind the ear and take pills according to a prescribed
regimen over an 8-week period. Half of the time the medications contain scopolamine and half
of the time they contain an "active" placebo called glycopyrrolate, a drug that produces side
effects similar to those that may be experienced with scopolamine, but that does not go into
the brain.
Participants come to the NIH Clinical Center every 4 to 5 days while taking the medication
and then for two follow-up visits over the next 2 weeks for a physical exam and evaluations
with clinical rating scales. In addition, participants are asked to undergo two sessions of
cognitive testing and to have two positron emission tomography (PET) studies. Those who have
the PET scans also have a magnetic resonance imaging (MRI) scan. Participants can choose to
participate in the rest of the study without doing the PET scan.
PET is a diagnostic imaging tool that uses a radioactive chemical "tracer" to show cellular
activity in specific tissues of the body. For this procedure, a catheter (thin plastic tube)
is placed into an arm vein for injecting the tracer, and a second catheter is inserted into
an artery in the wrist to obtain arterial blood samples during the scan. The patient lies on
the scanner bed, wearing a special mask that is placed over the head to limit movement during
the scan. MRI uses a magnetic field and radio waves to produce pictures of the brain. For
this test, the subject lies on a table that is moved into the scanner (a metal cylinder),
wearing earplugs to muffle the noise of the machine during the scan.
Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies [Recruiting]
|
